• Thursday, Sep 23, 2021
  • Last Update : 08:45 pm

Bharat's Covid-19 shot shows high immune response, further study needed for elderly

  • Published at 06:53 pm March 9th, 2021
Indian Health Minister Harsh Vardhan
File Photo: Indian Health Minister Harsh Vardhan holds a dose of Bharat Biotech's Covid-19 vaccine called Covaxin, during a vaccination campaign at All India Institute of Medical Sciences (AIIMS) hospital in New Delhi on January 16, 2021 Reuters

The vaccine, India's first successful home-made shot against Covid-19, has attracted interest from more than 40 countries

A Covid-19 vaccine developed by India's Bharat Biotech is safe and has shown high levels of antibody response in a mid-stage trial, but follow-on studies are needed to evaluate the shot for children and older people, a peer-reviewed study showed.

The vaccine, India's first successful home-made shot against Covid-19, has attracted interest from more than 40 countries. The company said last week it had shown 81% efficacy in preventing symptomatic Covid-19, based on interim analysis of late-stage trials.

The double-dose vaccine showed significantly higher neutralizing antibody responses in Phase II than in Phase I due to the difference in dosing regimens that changed to a 4-week apart injection schedule from a 2-week course, researchers said in the study published in medical journal Lancet on Monday.

But it said the Phase II trial, which had 380 participants, enrolled a small number of participants aged 12–18 years and 55–65 years and follow-on studies are required to establish immunogenicity in children and in older people.

It also said that while the trial included participants from across nine Indian states, the study population lacked ethnic and gender diversity, "underscoring the importance of evaluating BBV152 (the vaccine) in other populations."

Female participants, for example, accounted for just one quarter of the study subjects.

Its Phase III study, Bharat Biotech said last week, has 25,800 participants aged 18-98 and include more than 2,400 people over the age of 60.

The peer-reviewed study is another positive for Bharat Biotech, which had drawn criticism in January after the Indian government approved the vaccine, called Covaxin, for emergency use without any efficacy data.

Less than 9% of the more than 18.2 million Indians vaccinated so far against Covid-19 had taken Covaxin as of Tuesday, government data showed.

Many politicians in India, including Prime Minister Narendra Modi, have chosen to be inoculated with the homegrown shot instead of a rival one developed by AstraZeneca Plc and Oxford University.

India, the world's biggest vaccine maker, aims to inoculate 300 million of its 1.35 billion people by August. It has reported 11.24 million Covid-19 infections, the highest number in the world after the United States, with 157,930 deaths.

Facebook 52
blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail